« Return to News Archives

URAC Releases Specialty Pharmacy White Paper

Thursday, October 6th, 2011

URAC Releases Specialty Pharmacy White Paper
Report Examines Growing Market with Focus on Patient-Centered Approach

Washington, D.C. – October 6, 2011 – URAC, the leading health care accreditation and education organization, has released its latest report, The Patient-Centered Outgrowth of Specialty Pharmacy. This report examines the growth of the specialty pharmacy market including the changes in U.S. demographics and health plan models, key issues at stake, predictions for the future of specialty pharmacies, and the role of accreditation.

While the definition of “specialty pharmacy” and “specialty drug” can vary, most agree that specialty drugs are expensive and complex. The Centers for Medicare and Medicaid Services defines drugs that cost more than $600 per month as specialty drugs, while other health plans put the monthly threshold at $1,200 per month. Often a specialty drug is used to treat a chronic condition and requires special handing and unique distribution and administration channels. It also can require high degrees of patient management and counseling. Currently the most common conditions that require specialty drugs are cancer, multiple sclerosis, and rheumatoid arthritis and other autoimmune diseases.

“Specialty pharmacies represent approximately 17 percent of total pharmaceutical revenues, or roughly $50 billion per year, and that percentage is expected to more than double by 2020,” said Janice Anderson, RPh, Director of Pharmacy Programs of URAC. “We developed this white paper to help payors, prescribers, pharmacy benefits managers, and consumers better understand the importance of specialty pharmacies and how a patient-centered care approach benefits all of the stakeholders.”

The white paper reveals that many health plans require that some specialty drugs be channeled through specialty pharmacy providers. For example, 71percent of Medicaid plans require that at least one therapy category – which may include treatments for hepatitis C, multiple sclerosis, rheumatoid arthritis, Crohn’s disease, hemophilia, and cancer – go through a specialty pharmacy. Sixty-four percent of Medicare Advantage Prescription Drug plans and 59 percent of commercial plans meet the same specialty pharmacy requirements.

Due to the complexity of specialty drugs, many payers prefer that specialty pharmacies achieve third-party accreditation to confirm their commitment to quality, cost containment and proper utilization. URAC’s Specialty Pharmacy Accreditation is the top choice of payers. The program includes quality measures and patient-centered standards that cover a broad range of elements related to patient management, pharmacy operations, specialty drug management, and customer service, communications, and disclosure.

“We know how complicated specialty drug regimens can be for patients, providers, and pharmacies. Our Specialty Pharmacy Accreditation helps pharmacies establish best practices to improve safety and efficiency, while providing payers and patients the reassurance that an independent third party has reviewed the program,,” said Christine G, Leyden, Chief Accreditation Officer of URAC. “As the specialty drug market continues to grow, ensuring that there are measures and quality standards in place benefits everyone. Our integration of disease management, case management, and care coordination standards with the specialty pharmacy practices ensure that the patient’s needs are front and center.”

Organizations that have already achieved or are in the process of receiving URAC Specialty Pharmacy Accreditation include the following:

  • Accredo Health Group, Inc.
  • Acro Pharmaceutical Services
  • Apothecary Shop of Deer Valley, Inc.
  • ASAP Pharmacy
  • Axium Healthcare Pharmacy, Inc.
  • Biologics, Inc.
  • BioPlus Specialty Pharmacy Services, Inc.
  • BioScrip, Inc.
  • Brame Huie Pharmacy
  • Burman’s Specialty Pharmacy, LLC
  • Caremark Rx, LLC
  • Centric Health Resources
  • Commcare Pharmacy
  • Coram RX
  • CuraScript
  • Cystic Fibrosis Services
  • Diplomat Pharmacy, Inc.
  • Drugco Pharamacies
  • Fresenius Medical Care Rx, LLC
  • Giannotto’s Pharmacy
  • Gilead Pharmacy
  • ICORE Healthcare
  • JVJ Pharmacists, Inc. dba University Chemists
  • KCC, Inc. dba Vital Care Rx
  • Kerr Health, LLC
  • Longs Drugs of Lexington, SC Inc.
  • Main Street Pharmacy
  • Mast Drug Company, Inc.
  • MedfusionRx, LLC
  • Medic Specialty Pharmacy
  • MedPro Rx, Inc.
  • OncologyRx Care Advantage
  • OncoSource Rx
  • OptumRx
  • Pharmaceutical Specialities, Inc.
  • Pharmacy Advantage
  • Portland Professional Pharmacy dba Ascend SpecialtyRx
  • Premier Kids Care, Inc.
  • Prime Aid Pharmacy, Inc.
  • Tyro Family Pharmacy
  • US Bioservices, an Amerisource Bergen Specialty Company
  • Village Fertility Pharmacy
  • Walgreens Specialty Pharmacy, LLC

To obtain a copy of the URAC white paper, The Patient-Centered Outgrowth of Specialty Pharmacy, visit www.urac.org/Whitepaper/PQM-Specialty_Pharmacy.pdf.  For more information about URAC’s Specialty Pharmacy accreditation or its suite of Pharmacy Quality Management products, please call 202-216-9010 or email businessdevelopment@urac.org or go to www.urac.org/pqm

###

For 25 years, URAC has been the independent leader in promoting health care quality through accreditation, education, and measurement. URAC offers a wide range of quality benchmarking programs that reflect the latest changes in health care and provide a symbol of excellence for organizations to showcase their validated commitment to quality and accountability. URAC’s evidence-based measures and standards are developed through inclusive engagement with a broad range of stakeholders committed to improving the quality of health care.

For more information about URAC, contact us.

Interested in accreditation?
Contact businessdevelopment@urac.org

Code of Conduct | Privacy Policy | Terms of Use

Social Media TextFollow us on FacebookFollow us on TwitterFollow us on Linked In